Clinical Trial

Capsaicin in Digital Osteoarthritis Versus Control

Study acronym: CADOR
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component. Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%). Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-31; most recent amendment 2025-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-03-12
Trial Details
NCT Number NCT06444919
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Grünenthal GmbH
Conditions Osteoarthritis Hand, Neuropathic Pain
Enrollment 120 participants
Start Date 2025-03-07
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-13